NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Time-Dependent and Sample-to-Sample Variations in Human Plasma Peptidome are Both Minimized Through Use of Protease Inhibitors

Author(s): Craft D, Yi Jizu, Gelfand CA

Publication: Analytical Letters, 2009, Vol. 42, Page 1398-1406

Review Paper? No

Purpose of Paper

The purpose of this paper was to compare the plasma peptidome  between EDTA blood collected into tubes with and without protease inhibitors both when blood was processed immediately and after a processing delay.

Conclusion of Paper

While plasma peptide content was greater when blood was collected into EDTA tubes that lacked protease inhibitors, EDTA plasma from collection tubes that contained a protease inhibitor cocktail displayed more uniform peptide spectra between individuals and more stable peptide content after a 4 hour processing delay. 

Studies

  1. Study Purpose

    The purpose of this study was to determine whether blood collected into tubes containing protease inhibitors display an altered EDTA plasma peptidome and to determine the effect of protease inhibitors on between-patient  variability. Blood was collected from three healthy individuals into two tubes: EDTA tubes, P100 tubes (contains EDTA and a protease inhibitor cocktail).  Blood was left in the original collection tube at room temperature for 0, 60, 120, 180, or 240 min prior to plasma processing by centrifugation and filtration. Peptide spectra were visualized after fractionation on a nano-HPLC system.

    Summary of Findings:

    Blood collected in tubes containing a protease inhibitor cocktail (P100 tubes), displayed more uniform peptide spectra following room temperature storage compared to those collected into EDTA tubes. Variability among peptide spectra between patients was also reduced among specimens collected in P100 tubes in comparison to EDTA tubes.  

    Biospecimens
    Preservative Types
    • None (Fresh)
    Diagnoses:
    • Normal
    Platform:
    AnalyteTechnology Platform
    Peptide HPLC
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Storage Time at room temperature 0 min
    60 min
    120 min
    180 min
    240 min
    Analyte Extraction and Purification Protease inhibitor No protease inhibitor added
    Cocktail
    Biospecimen Acquisition Type of collection container/solution BD Vacutainer PPT (EDTA)
    BD P100 (EDTA and Protease inhibitor cocktail)
  2. Study Purpose

    The purpose of this study was to determine whether blood collected into tubes containing protease inhibitors display an altered plasma peptidome, compared to EDTA plasma specimens, immediately or after a 240 min processing delay. Blood was collected from a single healthy individual into two tubes: EDTA, P100 tubes (contains EDTA and a protease inhibitor cocktail).  Blood was left in the original collection tube at room temperature for 0 or 240 min prior to plasma processing by centrifugation and filtration. Peptides extracted from plasma were analyzed by LC-MALDI-MS.

    Summary of Findings:

    Peptide content was greater in EDTA tubes compared to P100 tubes when plasma was processed immediately. However, when tubes were subjected to a 4 hour processing delay peptide content decreased considerable in EDTA tubes but remained stable in P100 tubes. Differences between tube types that were processed immediately suggest that proteolysis occurs rapidly in the absence of protease inhibitors.

    Biospecimens
    Preservative Types
    • None (Fresh)
    Diagnoses:
    • Normal
    Platform:
    AnalyteTechnology Platform
    Peptide MALDI-TOF MS
    Peptide HPLC
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Storage Time at room temperature 0 min
    240 min
    Analyte Extraction and Purification Protease inhibitor No protease inhibitor added
    Cocktail
    Biospecimen Acquisition Type of collection container/solution BD Vacutainer PPT (EDTA)
    BD P100 (EDTA and Protease inhibitor cocktail)

You Recently Viewed  

News and Announcements

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • Most Popular SOPs in March 2024

  • New SOPs Available

  • More...